Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Infantile haemangiomas (IHs) are common benign vascular tumours of infancy, most of which do not require treatment. Complications for which treatment is indicated include impairment of vital function by ocular or airway involvement, potential to cause significant disfigurement, and ulceration. Case reports, case series and anecdotal experience since 2008 have established that propranolol is a rapidly effective and generally well-tolerated treatment for IHs in comparison with previously available therapies such as corticosteroids, vincristine and interferon.1–4 Recently published recommendations provide a provisional set of best practices meant to standardise the approach to the use of propranolol for IHs (see box 1).
Link to full guideline
Information about current recommendations
In January 2013, a multispecialty group sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases published consensus recommendations entitled: ‘Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference.’5 The goal of the conference was ‘to develop a standardised, consensus-derived set of best practices for the use of propranolol in infants with infantile hemangioma.’ In all, 28 participants from five specialties (including paediatrics, dermatology, otolaryngology, cardiology, haematology/oncology) and 12 US institutions participated in the conference. These participants reviewed the available literature on propranolol use for IH and developed consensus protocols.
There are no previous guidelines …
Contributors HAB-B and LB: conception and design, manuscript draft and revision. HAB-B: final approval.
Competing interests None.
Provenance and peer review Commissioned; externally peer reviewed.